Pneumococcal 21-valent conjugate vaccine
Vaccineapproved
Approved
Jun 17, 2024
Clinical trial activity
19 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
16
Phase 3
16
Phase 4
0
Earliest trial started Jul 12, 2022 (NCT05420961)
Timeline
Indications
Approved for
Mechanism of action
- Streptococcus pneumoniaeImmunity, active
Streptococcus pneumoniae immunity, active
Approval history
- approvedAcceleratedJun 17, 2024
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07300267 | Phase 1 | Jan 21, 2026 | Merck |
| NCT07284654 | Phase 3 | Dec 1, 2025 | Vaxcyte, Inc. |
| NCT07247188 | Phase 3 | Nov 24, 2025 | Sanofi |
| NCT07168915 | Phase 1 | Oct 8, 2025 | Merck |
| NCT06975878 | Phase 3 | May 22, 2025 | Sanofi |
| NCT06838000 | Phase 3 | Feb 28, 2025 | Sanofi, Sanofi-Aventis |
| NCT06824181 | Phase 3 | Feb 27, 2025 | Sanofi |
| NCT06824194 | Phase 3 | Feb 18, 2025 | Sanofi |
| NCT06736041 | Phase 3 | Dec 16, 2024 | Sanofi-Aventis |
| NCT06611033 | Phase 1 | Sep 25, 2024 | Merck |
| NCT06177912 | Phase 3 | Jan 17, 2024 | Merck |
| NCT05696080 | Phase 3 | Feb 13, 2023 | Merck |
| NCT05633992 | Phase 3 | Jan 10, 2023 | Merck |
| NCT05569954 | Phase 3 | Nov 7, 2022 | Merck |
| NCT05526716 | Phase 3 | Sep 23, 2022 | Merck |
| NCT05464420 | Phase 3 | Aug 12, 2022 | Merck |
| NCT05425732 | Phase 3 | Jul 13, 2022 | Merck |
| NCT05393037 | Phase 3 | Jul 13, 2022 | Merck |
| NCT05420961 | Phase 3 | Jul 12, 2022 | Merck |
Showing 19 of 19 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 12 | 12 | 2 | 2022 |
| Sanofi | For profit | 5 | 4 | 1 | 2025 |
| Sanofi-Aventis | For profit | 2 | 2 | 1 | 2024 |
| Vaxcyte, Inc. | For profit | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1